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Abstract
Background: Worldwide hundreds of millions of schistosomiasis patients rely on treatment with a single drug, praziquantel.
Therapeutic limitations and the threat of praziquantel resistance underline the need to discover and develop next
generation drugs.
Methodology: We studied the antischistosomal properties of the Medicines for Malaria Venture (MMV) malaria
box containing 200 diverse drug-like and 200 probe-like compounds with confirmed in vitro activity against
Plasmodium falciparum. Compounds were tested against schistosomula and adult Schistosoma mansoni in vitro. Based
on in vitro performance, available pharmacokinetic profiles and toxicity data, selected compounds were investigated in
vivo.
Principal Findings: Promising antischistosomal activity (IC50: 1.4–9.5 mM) was observed for 34 compounds against
schistosomula. Three compounds presented IC50 values between 0.8 and 1.3 mM against adult S. mansoni. Two promising
early leads were identified, namely a N,N9-diarylurea and a 2,3-dianilinoquinoxaline. Treatment of S. mansoni infected mice
with a single oral 400 mg/kg dose of these drugs resulted in significant worm burden reductions of 52.5% and 40.8%,
respectively.
Conclusions/Significance: The two candidates identified by investigating the MMV malaria box are characterized by good
pharmacokinetic profiles, low cytotoxic potential and easy chemistry and therefore offer an excellent starting point for
antischistosomal drug discovery and development.
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Introduction
With hundreds of millions of people living at risk of infection
and 207 million people infected with schistosomes worldwide,
schistosomiasis is one of the most devastating parasitic diseases in
tropical countries and remains a major public health problem,
especially in Sub-Saharan Africa [1,2]. Schistosoma haematobium, S.
japonicum and S. mansoni are the main schistosome species,
responsible for the largest number of infections [3,4].
A major cornerstone of schistosomiasis control programs is the
treatment of at risk populations with praziquantel, with the aim of
controlling morbidity and preventing associated mortality [5–7].
Praziquantel, discovered in the 1970’s, is the only drug available
for the treatment of schistosomiasis [7–9].
Despite many benefits of praziquantel, most notably its
high efficacy and excellent tolerability, the drug has major
drawbacks, most importantly its inefficacy against juvenile
schistosomes [10,11]. Furthermore the increasing administration
of praziquantel to millions of people annually [12] results in high
drug pressure, and thus drug-resistant parasites are likely to evolve
[13].
These facts underline the urgent need to discover and develop
the next generation of antischistosomals. Only a few compounds
are presently being studied in the preclinical phase [14–17] and
none of the candidates evaluated in clinical trials in the past years
(e.g. mefloquine [18] or the artemisinins [19]) (Figure S1) met the
target product profile for a novel antischistosomal drug [20].
Interestingly many of the chemical scaffolds that revealed
promising activity against schistosomes had their origin in
antimalarial research and discovery [21]. The blood-feeding
characteristic that both parasites have in common forms the basis
for the dual antimalarial and antischistosomal activity of drugs
interfering with the parasites’ hemoglobin degradation pathway
[22,23].
The aim of the present study was to investigate the antischis-
tosomal properties of the Medicines for Malaria Venture (MMV)
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malaria box containing 200 diverse drug-like compounds (which
fit in the ‘‘Lipinski space’’ or rule of five), as a starting point for
oral drug discovery and development, and 200 diverse probe-like
compounds (no filters applied). Note that all of the compounds in
the box have confirmed activity against the blood-stage of
Plasmodium falciparum in vitro and are commercially available [24].
Studying this diverse set of molecules might reveal an entirely new
chemical scaffold for antischistosomal drug discovery and there-
fore fill up the empty antischistosomal drug pipeline.
At the Swiss Tropical and Public Health Institute (Swiss TPH),
drugs were first studied against schistosomula in vitro followed by a
re-evaluation of successful hits on adult S. mansoni. In parallel all
the drugs were independently tested at the London School of
Hygiene and Tropical Medicine (LSHTM) in an in vitro adult
worm assay. Possible class effects and structure-activity relation-
ships are discussed. The onset of action and IC50/IC90 ratios were
studied. Based on in vitro performance and available pharmaco-
kinetic profiles as well as toxicity data, selected compounds were
investigated in vivo.
Methods
Drugs and Media
The MMV Box [24], containing 400 compounds as stock
solutions dissolved in dimethylsulfoxide (DMSO), concentration
10 mM, was kindly provided by MMV/SCYNEXIS, Inc.
(Geneva, Switzerland; Durham, USA). For the in vitro studies on
adult worms at the Swiss TPH and the in vivo studies in mice
5–100 mg of 1: MMV000963, 2: MMV665852, 3: MMV665807,
4: MMV019555, 5: MMV019918, 6: MMV000445, 7:
MMV019780, 8: MMV665927, 9: MMV665941, 10:
MMV000634, 11: MMV665830, 12: MMV666054, 13:
MMV009063, 14: MMV007591, 15: MMV665969, 16:
MMV666070, 17: MMV007224, 18: MMV665794, 19:
MMV666057, and 20: MMV665799 were purchased from Specs
(Delft, Netherlands), and MolPort (Riga, Latvia). Praziquantel
was purchased from Sigma-Aldrich (Buchs, Switzerland) GmbH.
Compounds 1–20 were dissolved in DMSO for drug stock
solutions of 10 mg/ml for in vitro evaluations. Culture medium for
newly transformed schistosomula (NTS) was made by supple-
menting Medium 199 (Lubioscience, Lucerne, Switzerland)
with 5% heat-inactivated fetal calf serum (iFCS), penicillin
(100 U/ml), and streptomycin (100 mg/ml) (Lubioscience,
Lucerne, Switzerland). Culture medium for adult worms was
prepared by supplementing RPMI 1640 with 5% iFCS, penicillin
(100 U/ml), and streptomycin (100 mg/ml).
Preparation of Newly Transformed Schistosomula (NTS)
S. mansoni cercariae (Liberian strain) were harvested from
infected intermediate host snails (Biomphalaria glabrata) following in-
house standard procedures. Collected cercariae were mechanically
transformed to NTS as described previously [25,26]. The obtained
NTS suspension was adjusted to a concentration of 100 NTS per
50 ml using supplemented Medium 199. NTS suspensions were
incubated (37uC, 5% CO2 in ambient air) for a minimum of 12 to
24 hours until usage to ensure completed conversion into
schistosomula [27].
Ethics Statement
In vivo studies were conducted at the Swiss TPH, Basel, and
approved by the veterinary authorities of the Canton Basel-Stadt
(permit no. 2070) based on Swiss cantonal and national regula-
tions. Experimentation at LSHTM was carried out under the UK
Animals Scientific Procedures Act 1986 with approval from the
LSHTM Ethics committee.
Maintenance of Mice and Infection with S. mansoni
Animals (female NMRI, 3-week old, weight ca. 14 g) were
purchased from Charles River (Sulzfeld, Germany) and allowed to
adapt under controlled conditions (temperature ca. 22uC; humid-
ity ca. 50%; 12-hour light and dark cycle; free access to rodent diet
and water) for one week. Mice were infected by subcutaneous
injection with ,100 S. mansoni cercariae each, harvested from
infected snails. For in vitro studies on adult flukes, schistosomes
were collected from the hepatic portal and mesenteric veins of
infected mice 7–8 weeks post infection [28]. Freshly harvested
schistosomes were placed in supplemented RPMI culture medium,
quickly rinsed, and stored at 37uC, 5% CO2 until usage.
In Vitro Compound Screening Cascade on S. mansoni at
Swiss TPH
Initially, all compounds were tested at a concentration of
100 mM on S. mansoni NTS. Active compounds progressed into a
secondary screening at 33.3 mM. For this purpose drug stock
solutions were diluted in 96-flat bottom well plates (BD Falcon,
USA) with supplemented Medium 199 and 50 ml of prepared NTS
suspension (100 NTS/well) to the desired final concentration of
100 mM or 33.3 mM, respectively. Each drug was tested at least in
triplicate and the highest concentration of DMSO served as
control. Plates were incubated at 37uC, 5% CO2. NTS were
evaluated by microscopic readout (Carl Zeiss, Germany, magni-
fication 80–1206) using a viability scale as previously described
with regard to death, changes in motility, viability, and morpho-
logical alterations 72 hours post drug exposure [25,26]. To ensure
the accuracy of our assay, 45 compounds that lacked activity at
one of the tested concentrations, were randomly selected and
retested at 33.3 mM. Compounds that killed the NTS at 72 hours
after exposure in at least one well were deemed active and selected
for further testing.
In the next step, the IC50 was determined for active compounds
from the preceding screens. Drug dilution series were prepared in
96-flat bottom well plates with concentrations 2.1, 4.2, 8.4, 16.7,
and 33.3 mM using supplemented culture medium. The prepared
NTS suspension was then added to each well and plates were
incubated at 37uC, 5% CO2. NTS incubated in the presence of
the highest DMSO concentration and praziquantel served as
Author Summary
To date, praziquantel is the only available drug for the
treatment of the tropical neglected disease schistosomiasis
and is widely used in morbidity control programs. To
discover new chemical scaffolds for the treatment of
schistosomiasis, we investigated the Medicines for Malaria
Venture malaria box containing 200 diverse drug-like and
200 probe-like compounds with known antimalarial
activity against Schistosoma mansoni. Compounds were
first investigated on the larval stage of S. mansoni,
followed by testing against adult worms in vitro and by
in vivo studies of lead candidates. We identified two
entirely new chemical scaffolds: the N,N9-diarylurea and
2,3-dianilinoquinoxaline derivatives with antischistosomal
in vitro activity in the sub micromolar range and significant
activity in the mouse model. Since both compounds offer
a good pharmacokinetic profile, low cytotoxic potential
and easy chemistry, structure-activity relationship studies
should be launched.
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control. Drug effects on NTS were evaluated 72 hours post
exposure, using a viability scale, as described above. Each
concentration was tested in duplicate and experiments were
repeated once.
Compounds presenting IC50 values#10 mMwere then tested at
a concentration of 33.3 mM on adult worms in duplicate. Drug
stock solutions (10 mM) were diluted in supplemented RPMI 1640
culture medium reaching a final concentration of 33.3 mM in 24-
flat bottom well plates (BD Falcon, USA) within a final volume of
2.4 ml. At least three schistosomes of both sexes were added to
each well. Schistosomes incubated in the presence of the highest
concentration of DMSO served as control. Plates were incubated
for 72 hours at 37uC, 5% CO2. Seventy-two hours post drug
exposure S. mansoni were examined phenotypically by microscope
using the motility scale described before [29]. Drugs leading to the
death of schistosomes 72 hours post exposure were characterized
further and their IC50 (IC90) values were determined. Specifically,
drug dilution series were prepared in 24-flat bottom well plates
(BD Falcon, USA) with concentrations of 0.31, 0.93, 2.78, 8.33,
and 25.0 mg/ml using supplemented RPMI culture medium and
freshly prepared drug stock solutions (10 mg/ml). At least three
schistosomes of both sexes were added to each well and plates were
incubated at 37uC, 5% CO2. Parasites incubated in the highest
DMSO concentration and praziquantel served as controls. Drug
effects were evaluated 72 hours post exposure as described above.
Each concentration was tested in duplicate and trials were
repeated once.
In Vitro Screening on Adult Schistosomes at LSHTM
Adult worm drug testing was performed as previously reported
[29] with some modifications as described. Worms of a Puerto
Rican strain of S. mansoni were obtained by portal perfusion of
CD1 mice (Charles River, UK) 6 weeks post-infection. Three pairs
of worms were added to the wells of 48-well plates (Nunc, UK) in
1 ml complete DMEM medium supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin (cDMEM). Compounds were tested at 15 mM
containing 0.15% DMSO in single wells. Negative controls
contained worms cultured in cDMEM alone and in cDMEM
with 0.15% DMSO. Positive control wells contained worms
cultured in praziquantel (Sigma-Aldrich, UK) at 10 mM. Cultures
were incubated at 37uC and 5% CO2. Effects were assessed on day
5 of culture using an inverted microscope (Leitz Diavert Wetzlar,
Germany). Any compounds producing complete immotility or
$70% worm motility inhibition plus severe morphological
damage were considered hits in the primary screen [29]. Active
compounds were then tested for IC50 value determination at a
concentration range from 0.55–15 mM in single wells.
In Vitro Characterization of Lead Candidates on Adult
Schistosomes
The onset of action (length of time needed before an
antischistosomal effect was visible) was determined for selected
compounds in vitro by evaluating the IC50 at a time-range of 1–
72 hours (1, 2, 4, 7, 10, 24, 48, and 72 hours) post drug exposure,
as described above. The onset of action of praziquantel was also
studied. Additionally, possible protein binding effects were studied
for three lead candidates and praziquantel. For that purpose
RPMI medium was supplemented with two different iFCS
concentrations (0% and 50%) and IC50 values were calculated
for the different conditions. Furthermore, IC50 values were
determined after varying drug exposure times (1, 2, or 4 hours)
followed by incubation in drug free RPMI medium for 72 hours.
In Vivo Screening Using the Chronic S. mansoni Mouse
Model
Groups of 3–4 NMRI mice characterized by a patent S. mansoni
infection (49 days post-infection) were treated orally with the test
drug using either single oral doses of 400 mg/kg or 80 mg/kg
administered on four consecutive days. An additional dosage
regimen of 100 mg/kg administered four times every 4 hours was
tested for the 2 most active compounds (2, 17). Compounds
were freshly prepared in an aqueous hydroxypropyl methyl
cellulose (HPMC) (1%): DMSO (95:5) formulation. Eight to
sixteen untreated mice served as controls. Fourteen days post-
treatment animals were killed by the CO2 method and were
dissected and the worms were sexed and counted [28]. Mean
worm burdens of treated mice were compared to the mean worm
burden of untreated animals and worm burden reductions were
calculated.
Statistics
Parasite viability values of NTS and adult schistosomes obtained
from microscopic evaluation were averaged (means (+/2 standard
deviation)) using Microsoft Excel. IC50 and IC90 values of test
compounds were determined using the CompuSyn software
(Version 3.0.1, 2007; ComboSyn Inc., USA) and Microsoft XLfit
version 5.1.0.0 (2006–2008 ID Business Solutions Ltd). Selectivity
indices were calculated by dividing the IC50 of the MRC-5 cells-
fibroblast cytotoxicity data by the IC50 of the adult worm assay.
The Kruskal-Wallis test was applied for in vivo studies, comparing
the worm burden of the treated animals and control animal
groups. A difference in worm burden was considered to be
significant at a significance level of 5% (StatsDirect, version 2.7.2.;
StatsDirect Ltd., UK).
Results
In Vitro Activity Determined on NTS and Adult
Schistosomes at Swiss TPH
Exposing schistosomula to the test drugs (n = 400) at a
concentration of 100 mM resulted in death of NTS for 45% of
the tested compounds (n = 179). Schistosomicidal effects were
observed for 18% of these active compounds (n = 72) at the lower
concentration of 33.3 mM (Figure 1). A diverse range of chemical
scaffolds was observed amongst active compounds. Successful
candidates were characterized further on NTS. Promising
antischistosomal activity (IC50: 1.4–9.5 mM) was observed for 34
compounds, two of which were identified during our quality
control re-evaluation of 45 compounds and nine of which showed
comparable or increased activity (IC50: 1.4–2.4 mM) to prazi-
quantel (IC50: 2.2 mM).
All hits (IC50,10 mM) (n= 34) were next tested at a concen-
tration of 33.3 mM on adult S. mansoni. Seventy-two hours post
drug exposure, 16 (1–16) of these compounds (Table S1) killed the
adult worms. Four of the ten compounds with high activities
(IC50,2.5 mM) on NTS lacked antischistosomal activity on adult
worms. The 16 active candidates were further characterized by
IC50 value determination. The highest in vitro activities were
observed for the diaminoquinazoline derivative 1 (IC50: 0.8 mM)
the diarylurea 2 and diarylamide 3, presenting IC50 values of 0.8
and 1.3 mM, respectively (PZQ: 0.2 mM). IC50 values ranging
from 2.6–9.2 mM were calculated for compounds 4–11, whereas
only moderate activity (IC50 values .10 mM) was determined for
five compounds (12–16). Compounds with IC50.10 mM were
excluded from further consideration, meaning only eleven
compounds were considered as hits.
Antischistosomal Leads Identified from Open Access Malaria Box
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In Vitro Activity Determined on Adult Schistosomes at
LSHTM
Forty-four compounds were classified as hits (compounds
producing complete immotility or $70% worm motility inhibition
plus severe morphological damage) against adult S. mansoni in vitro
at a concentration of 15 mM. These compounds were further
tested for IC50 values (Table S1). Twelve compounds showed IC50
values .15 mM. Fourteen compounds revealed IC50 values
between 10–15 mM. Eighteen compounds had IC50 values
,10 mM. To provide a comparison with the Swiss TPH assays,
the 32 hits were subsequently tested using the schistosomula assay
at LSHTM [30]. This showed generally good concordance with
the LSHTM adult assay, in that all adult hits with IC50,10 mM
were also hits in the larval assay (Table S1).
Selection of Lead Candidates
Based on in vitro performance on the adult worms (Table S1),
toxicity, pharmacokinetic (PK) properties and availability of the
compounds, five lead candidates (1, 2, 5, 8, 17) (Figure 2) were
selected for in vivo testing and in depth characterization in vitro. In
more detail, 11 compounds were excluded after comparing their
IC50 values and PK parameters (Cmax, tmax, t1/2, AUC). Four
compounds showed poor antischistosomal activity (IC50.10 mM)
and four compounds showed poor bioavailability (Cmax,IC50 of
the corresponding compound). Ten compounds were character-
ized by low selectivity indices (SI,1) and two were not
commercially available.
Four active compounds were derivatives belonging to the class
of diarylureas and two compounds were characterized as
dianilinoquinoxalines. Only the most active candidate of each
chemical group, compound 2 and compound 17, was selected for
in vivo studies. A summary of the IC50 values, toxicity and
pharmacokinetic parameters of the lead candidates is provided in
Table 1.
In Vitro Characterization of Lead Candidates on Adult
Schistosomes
The onset of action was studied in compounds selected for in vivo
testing (n = 5) and compared to the onset of action for praziquantel
(Figure 3). Compound 2 was the fastest acting drug, presenting an
IC50,5 mM already after 1 hour of in vitro exposure, followed by
compound 17 with an IC50,10 mM, 1 hour post incubation.
Compound 1 was intermediate in speed with an onset time of
7 hours post-incubation. Compound 8 had fully exerted its
antischistosomal properties 24 hours following incubation, while
compound 5 was slow acting (exposing its full antischistosomal
activity only 72 hours post treatment). In comparison, praziquan-
tel exposed its entire antischistosomal activity already after 1 hour
of drug exposure (IC50: 0.2 mM).
The determined IC90 values of the lead candidates were 2–5
fold higher than the observed IC50 values 72 hours post exposure
and thus the concentration-response curves for these compounds
are quite steep (Table 2). Comparatively, praziquantel even
showed a 13-fold difference between the two values. Praziquantel
Figure 1. Screening flow. Screening was conducted at the Swiss TPH (screening cascade I; steps A–E and Quality control): Primary screening steps
(yes/no filters) of 100 mM and 33.3 mM resulted in 179 and 72 hits, respectively. Active compounds (n = 72) moved on to Step C and IC50 values were
evaluated on NTS. Thirty-four compounds showed activities with IC50 values ,10 mM and pre-screening was conducted on adult schistosomes (Step
D). Active compounds (n = 16) with schistosomicidal effects at 33 mM compound concentration were further characterized (step E). The quality
control represents randomly selected compounds from compounds classified as non-active from the pre-screening steps (step A/B) on NTS which
were re-evaluated in step B. In parallel, all compounds (n = 400) were studied at the LSHTM in London (screening cascade II): step A, all 400
compounds were screened on S. mansoni adults at 15 mM. Step B: 44 compounds were active and these were then tested for IC50 determination on
adult worms. From both screening cascades, five compounds were selected for in vivo testing based on pharmacodynamic and pharmacokinetic
properties as well as toxicity.
doi:10.1371/journal.pntd.0002610.g001
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lead very quickly to a strong motility inhibition and morphological
changes, whereas higher concentrations (IC90: 2.0 mM) were
necessary to actually kill the worms.
In Vivo Findings
Compound 2 and 17 revealed the highest in vivo activity with
worm burden reductions (WBR) of 52.5% (dosage 16400 mg/kg;
p,0.005) and 53.4% (dosage 46100 mg/kg; p,0.005), respec-
tively (Table 3). In addition, both treatment regimens using
multiple doses of compound 2 resulted in significant worm burden
reductions of 46.0% (4680 mg/kg; p,0.005) and 31.2%
(46100 mg/kg; p,0.05). Treatment with a single 400 mg/kg
dose of compound 17 resulted in a significant worm burden
reduction of 40.8% (p,0.05), while multiple treatment courses of
80 mg/kg over four consecutive days achieved a lower effect
(WBR: 25.5%, p,0.05). Compounds 1, 5, and 8 lacked in vivo
activity (WBR 0–18.7%). No significant differences were observed
between total and female worm burden reductions.
Protein-Binding and Short-Term Drug Exposure of Leads
Compound 17 showed a 7-fold increase in activity in iFCS-free
medium (IC50: 0.3 mM) versus incubation in 50% serum
supplemented medium (IC50: 2.1 mM) (Table S2). A strong
increase in activity in serum free medium was observed for
praziquantel (IC50: 0.02 mM). No altered activities were detected
for compound 2 within varying iFCS-concentrations. Short-term
exposure of schistosomes to compound 2 or praziquantel (1–
4 hours) followed by incubation in drug free medium for 72 hours
resulted in high IC50 values, ranging from 51.1 mM (1 hour) to
24.6 mM (4 hours) for compound 2 and from 96.1 mM to 7.7 mM
for praziquantel (Figure S3). These values are much higher than
the IC50 values determined when the worms are continuously
exposed to the drugs for 72 hours (2: IC50: 0.8 mM; PZQ: IC50:
0.2 mM). Incubation of schistosomes for 4 hours with compound
17 achieved similar effects (IC50: 1.3 mM) (Figure S3) as described
for the 72 hours exposure time (IC50: 0.8 mM) (Table S2).
Discussion
The aim of this study was to investigate the antischistosomal
potential of 200 drug-like and 200 probe-like compounds
assembled in the MMV Malaria Box. The MMV Malaria Box
provided a unique opportunity: commercially available com-
pounds with confirmed in vitro activity against P. falciparum serve as
good starting material for antischistosomal R&D, as many
antimalarials have antischistosomal activity [16,23,31]. In addi-
tion, and in line with the target characteristics of a trematocidal
lead candidate [20], properties of the drug-like compounds are
commensurate with oral absorption and the presence of known
toxicophores is minimized.
NTS were used as a prescreening tool at Swiss TPH, since their
use greatly reduces the need for laboratory animals and thus is a
major contributor to the 3 R rules (replace, reduce, refine) [25].
Nearly half of the tested compounds (45%) presented schistoso-
micidal effects on the schistosomular stage at a concentration of
100 mM. Given this high hit rate, compounds which were not
lethal on NTS did not progress further. This might be a limitation
of the Swiss TPH screening, since many effective anthelmintics
(including praziquantel at low concentrations) cause paralysis
rather than death of worms [32]. Thirty-four of the active
compounds had IC50 values ranging from 1.4 to 9.5 mM,
suggesting that both parasites, P. falciparum and S. mansoni, have
a similar drug sensitivity profile. About half of the compounds
active against NTS (n= 16) revealed good to moderate activity on
Figure 2. Chemical structures of the five lead compounds selected for in vivo studies.
doi:10.1371/journal.pntd.0002610.g002
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the adult stage (IC50: 0.8–22.3 mM). Several compounds that
showed high antischistosomal effects on schistosomula lacked
activity on adults. This phenomenon, where the hit rates were
higher against the larval stages than against the adult stages, has
been previously reported [14,33]. A higher sensitivity of the larval
stage, or mode of action dependent effects might partially explain
this higher hit rate: for example recent studies with various
peroxide classes documented less activity on the adult stage than
on the NTS stage [15].
The parallel screening at LSHTM screened all compounds
directly on adult schistosomes. Thirteen additional compounds
active against adult worms (IC50,10 mM) were identified at
LSHTM. Nine of these lacked activity against NTS at Swiss TPH
(Figure S2). Interestingly, these compounds showed activity against
NTS at LSHTM (Table S1). On the other hand, four compounds
with activity (IC50,10 mM) against NTS and adult worms
identified at Swiss TPH lacked activity in the LSHTM screen.
Overall, 22 compounds had an IC50,10 mM against adult worms
in at least one of the screens. Only five compounds were
characterized by an IC50,10 mM in both screenings. Strain
differences but also different ways of assay set up and readout
might offer an explanation for these results. Nonetheless, follow up
studies to clarify these issues are warranted.
Compound 2, a diarylurea, revealed the highest activity against
adult S. mansoni in vitro. In addition, our onset of action studies
revealed that it was the fastest acting compound, comparable to
praziquantel. The compound is characterized by an intriguingly
simple chemistry and can be easily synthesized. The class of N,N9-
diarylureas was recently found to activate heme-regulated
inhibitor kinase which inhibits translation initiation and plays a
central role in cancer initiation [34]. Additionally various N,N9-
diarylureas, including compound 2, have been investigated as
potential anti-cancer agents and were proposed as promising lead
compounds [35]. Significant worm burden reductions of 52.5%,
46.0%, and 31.2% were observed with compound 2 following
single oral dosing with 400 mg/kg, 80 mg/kg on four consecutive
days and 46100 mg/kg every four hours, respectively. This might
indicate that in vivo activity follows a time over threshold model
rather than it being Cmax driven. However, based on the in vitro
performance and pharmacokinetic data, a better in vivo outcome
was expected. Our follow-up in vitro studies, which studied protein
binding and the short-term drug exposure, might offer an
explanation for this discrepancy. Short incubation times (1 to
4 hours) were not sufficient to kill the worms, since most of the
parasites recovered 3 days later. Note that compound 2 is
characterized by a half-life (t1/2) of 4.7 hours and Cmax of 4.4 mM
at 46.3 mg/kg (po).
Additionally compound 17, a 2,3-dianilinoquinoxaline deriva-
tive, showed high in vitro (IC50: 0.83 mM) and significant in vivo
activity with WBRs between 53.4% (multiple po dose of 100 mg/
kg every four hours) and 40.8% (single po dose 400 mg/kg). This
series has been reported to show antimycobacterial activity [36].
The order of in vivo activity of the five selected candidates is in
line with the onset of action observed in vitro. The fastest acting
compound 2 exhibited the highest activity in vivo followed by
compound 17 (WBR: 40.8%). The discrepancy of excellent in vitro
performance of compound 17, but only moderate in vivo activity
might be explained by protein binding effects. Increased activities
were observed when incubated sans serum proteins in vitro.
Notably, short-term incubation of 4 hours was sufficient to exhibit
high antischistosomal effects for both drugs. Compounds 1, 5, and
8 acted slower (only 7–10 hours post exposure), and lacked activity
in vivo. This finding is in line with PK properties of these
drugs. Since the half-lives of the compounds are rather short
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(2.4–5.2 hours) plasma concentrations remain insufficiently long
above the IC50 values for the slow acting compounds to exert in
vivo activity.
Since a series of related derivatives was present in the MMV
Malaria Box, we carried out an initial structure-activity relation-
ship study by sourcing commercially available near neighbors for
compounds 1, 2, and 5 (Table S3). Exchanging the phenyl-group
of 1 with an ethanol group revealed a stage specific sensitivity with
activity on NTS, but lacked schistosomicidal effects on adult
worms. The substitution pattern on phenyl-residues of compound
2 influenced activity. For example, exchanging the para-chloro to a
para-fluro on one of the phenyl rings led to a two-fold decrease in
activity on NTS. Such subtle changes in activity require further
investigation with a larger set given the easy chemical accessibility
of derivatives.
Figure 3. Adult worm IC50 values of five in vivo candidates over time post drug exposure. Values were determined 1, 2, 4, 7, 10, 24, 48 and
72 hours after drug exposure. Values .33.3 mM are indicated with (//). PZQ: praziquantel.
doi:10.1371/journal.pntd.0002610.g003
Table 2. Adult worm IC50 and IC90 values of five in vivo
candidates compared to praziquantel 72 hours post drug
exposure.
Compound 1 2 5 8 17 PZQ
IC50 (mM) 0.6 0.5 3.7 2.8 0.3 0.2
IC90 (mM) 1.7 2.2 9.9 7.9 1.2 2.0
Ratio IC90/IC50 2.8 4.8 2.7 2.8 4.1 13.1
PZQ: Praziquantel.
doi:10.1371/journal.pntd.0002610.t002
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In conclusion, by screening the MMV malaria box on S. mansoni
we underlined the potential of compounds with an antimalarial
background on schistosomes. We identified two entirely new
chemical scaffolds: the N,N9-diarylurea (2) and 2,3-dianilinoqui-
noxaline derivatives (17) with antischistosomal in vitro activity in
the sub micromolar range and moderate in vivo activity. The
compounds offer promising drug characteristics such as a good
pharmacokinetic profile and low cytotoxic potential. Their easy
chemistry simplifies further drug optimization steps and offers an
excellent starting point for antischistosomal drug discovery and
development.
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